About
Akers Nanotechnology is a leading global rapid diagnostic test developer and supplier, and vaccine and pharmaceutical supplier.
- Supplier of rapid diagnostic tests, vaccines, and pharmaceuticals
- Developer, manufacturer, and supplier of proprietary rapid diagnostic tests for health and wellness and infectious diseases
- Strategic partnerships with suppliers of non-proprietary products
Divisions
COVID-19 and Infectious Diseases: Akers Nanotechnology provides the products and services required for your mission to beat COVID-19. We're doing our part in the fight against COVID-19 and other infectious diseases by developing, manufacturing, and supplying COVID-19 rapid antibody tests, and by supplying COVID-19 rapid nasal antigen tests, COVID-19 vaccines, and Influenza vaccines.
Health and Wellness: Akers Nanotechnology develops, manufactures, and distributes mobile health tests (mHealthTests™) which provide instant information on health and metabolism that enables healthy lifestyle choices based on our proprietary nanotechnology and digital application platforms. Nanotechnology for a Healthier Lifestyle
Specialty Pharmaceuticals: Akers Nanotechnology specializes in the wholesale of pharmaceutical products that are in short supply.
Products & Solutions
- Ozempic
- ImmuTrak™ Rapid COVID-19 Urine Antibody Test US
- ImmuTrak™ Rapid COVID-19 Urine Antibody Test CE
- ImmuTrak™ Rapid COVID-19 Blood Antibody Test
- COVID-19 Rapid Antigen Test - multiple brands
- COVID-19 Therapeutics - Paxlovid
- Lidocaine
- COVID-19 Vaccines - multiple brands
- Influenza Vaccines - multiple brands
- KetoFit™
- OxiFit™
- Immunity Strategy
- ImmuTrak™ Rapid COVID-19 Saliva Antibody Test (Coming Soon)
- Rapid SARS-CoV-2 Breath Test (In Development)
Core Competencies: research and development, manufacturing, commercialization, distribution, product approvals, regulatory affairs
Markets served (USA & International): commercial, wholesale and distribution, diagnostics, government, military, NGOs, occupational health, managed care organizations, fitness and wellness
Global footprint
Distinct record of innovation and success: Developed, patented, and commercialized numerous unique rapid diagnostic tests, including for infectious diseases, STDs, drugs of abuse, alcohol, adverse drug reactions, cholesterol, ketosis, oxidative stress, and blood type.
Seasoned, veteran management team has been working together for 40+ years.
Akers Nanotechnology is a leader in the personal healthcare revolution of the Internet of Medical Things, and our extensive experience in the medical diagnostics industry, combined with new, cutting-edge nanotechnology platforms, positions us to accomplish just that.
The Company manufactures its products at its facilities and with subcontractors.
Markets served (USA & International): commercial, wholesale and distribution, diagnostics, government, military, NGOs, occupational health, managed care organizations, fitness and wellness
Global footprint
Distinct record of innovation and success: Developed, patented, and commercialized numerous unique rapid diagnostic tests, including for infectious diseases, STDs, drugs of abuse, alcohol, adverse drug reactions, cholesterol, ketosis, oxidative stress, and blood type.
Seasoned, veteran management team has been working together for 40+ years.
Akers Nanotechnology is a leader in the personal healthcare revolution of the Internet of Medical Things, and our extensive experience in the medical diagnostics industry, combined with new, cutting-edge nanotechnology platforms, positions us to accomplish just that.
The Company manufactures its products at its facilities and with subcontractors.
FDA REG: 3016696612New Jersey Drug and Medical Device Registration: 5005855CAGE CODE: 8RFL6NAICS CODES: 541713, 423450UEI: CK8WFQTLYMV9
Raymond F. Akers, Jr., Ph.D. is the Founder and CEO of Akers Nanotechnology. He has spent the past 40 years as an innovator in rapid diagnostic test products. He has developed, patented, and commercialized numerous unique rapid diagnostic tests, including for infectious diseases, STDs, drugs of abuse, alcohol, adverse drug reactions, cholesterol, ketosis, oxidative stress, and blood type. He has also worked in the supply of rapid diagnostic tests, pharmaceuticals, and vaccines. He has taken two of his companies public in the IPO process, one on the NASDAQ and one on the London Stock Exchange's Alternative Investment Market. He holds a doctorate in Neuroscience from Northwestern University and a B.A. in Biology from Saint Joseph's University.